Patient-reported Outcome Research
In order to better consider the needs of patients in cancer therapy, we are responsible for the area of patient-reported outcomes (‘the success of therapy as documented by the patients themselves’) and quality of life in numerous randomised clinical trials and registry studies dealing with the improvement of cancer therapy.
The aim is to incorporate these previously under-researched aspects holistically into treatment decisions, both within the individual studies and in overarching research.
Ongoing (recruiting) studies/projects
Pasireotide as Maintenance Treatment with monthly deep intramuscular injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor.
In cooperation with Prof. Dr. Richard Schlenk, National Centrum for Tumor Diseases (NCT), Heidelberg
For actual information please look here
Clinical study
TROPHIT1: A Randomized, Open Label, Multicenter Phase II/III Trial of Sacituzumab Govitecan Compared to Standard of Care in Metastatic, Refractory Colorectal Cancer Patients.
In cooperation with PD Dr. med. Bruno Christian Köhler, National Center for Tumor Diseases (NCT), Heidelberg.
Clinical study
COGNITION-GUIDE Phase II-Study
Within the seven-arm umbrella phase-II clinical trial COGNITION-GUIDE, we aim to deliver molecularly-tailored cancer care by implementing an additional response- and genomics-guided post-neoadjuvant therapy after finishing the guideline-compliant post-neoadjuvant treatment in high-risk breast cancer patients with residual cancer burden after neoadjuvant therapy to reduce the substantial risk of local and distant relapse.
In cooperation with Prof. A. Schneeweiss and Prof. R. Schlenk, National Center for Tumor Diseases (NCT), Heidelberg
Clinical study
CRAFT
Continuous Reassessment with Flexible Extension in Rare Malignancies Study, Treatment stratification of younger adults with advanced-stage cancers and patients with rare tumors based on whole-genome sequencing, transcriptome sequencing, and DNA methylation analysis.
In cooperation with Prof. R. Schlenk, National Center for Tumor Diseases (NCT), Heidelberg
Register study
„A prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients with Myeloid Neoplasms"
The Myeloid Neoplasms Biology and Outcome Project
In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg
Register study
"A prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients with Soft-tissue and Bone Sarcoma"
A prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients with Soft-tissue and Bone Sarcoma.
In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg
Studies with completed recruitment and ongoing research
IntenSify
An open-label Phase I Trial of the CYP3A Inhibitor Cobicistat and the cytostatics Gemcitabine and nab-Paclitaxel in Patients with Advanced Stage or metastatic Pancreatic Ductal Adenocarcinoma to evaluate the combination's Pharmacokinetics, Safety and Efficacy.
In cooportaion with PD Dr. N. Hohmann, National Center for Tumor Diseases (NCT), Heidelberg
GnG "Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without glasdegib in older patients with newly diagnosed AML"
The study is a randomized phase III trial with a 2x2 factorial design with measurable residual disease and event-free survival as primary endpoints, respectively.
In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg and the Medical University of Heidelberg
Q-HAM “Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD”
Phase II clinical trial.
In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg and the Medical University of Heidelberg
